Trials / Conditions / Secondary Hypogonadism

Secondary Hypogonadism

20 registered clinical trials studyying Secondary Hypogonadism — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Intratesticular Artery Resistive Index Changes After Varicocelectomy NCT07517952	Assiut University	N/A
Unknown	Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men NCT02443090	NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)	Phase 2
Completed	An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolab NCT02274181	Repros Therapeutics Inc.	Phase 1
Completed	A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotr NCT01993225	Repros Therapeutics Inc.	Phase 3
Completed	A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotr NCT01993212	Repros Therapeutics Inc.	Phase 3
Completed	Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function NCT01923857	Repros Therapeutics Inc.	Phase 1
Completed	Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function NCT01923870	Repros Therapeutics Inc.	Phase 1
Completed	Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism NCT01739595	Repros Therapeutics Inc.	Phase 3
Completed	An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism NCT01739582	Repros Therapeutics Inc.	Phase 3
Completed	Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism NCT01532414	Repros Therapeutics Inc.	Phase 3
Completed	Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism NCT01534208	Repros Therapeutics Inc.	Phase 3
Completed	The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testost NCT01386606	Repros Therapeutics Inc.	Phase 2
Completed	Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism NCT01270841	Repros Therapeutics Inc.	Phase 2
Completed	Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus NCT01191320	Repros Therapeutics Inc.	Phase 2
Completed	Pharmacokinetic Study to Determine Time to Steady-state NCT00911586	Clarus Therapeutics, Inc.	Phase 2
Completed	The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups NCT01454011	Gulhane School of Medicine	Phase 4
Completed	To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone NCT00706719	Repros Therapeutics Inc.	Phase 2
Completed	Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism NCT00962637	Repros Therapeutics Inc.	Phase 3
Completed	Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonad NCT00467870	Endo Pharmaceuticals	Phase 3
Completed	Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism NCT01067365	Repros Therapeutics Inc.	Phase 3